KRAS作为原癌基因家族的核心成员之一，编码小GTP酶。正常情况下，KRAS蛋白通过结合GTP（激活态）或 GDP（失活态）进行状态的转换，调控细胞增殖、分化、凋亡及迁移等关键生理过程。当KRAS发生突变时，其GTP水解活性受阻，蛋白持续处于GTP结合的激活状态，导致下游信号通路过度激活，驱动细胞恶性转化，最终引发细胞异常增殖，并与细胞的侵袭性、转移性及不良表型密切相关。由于KRAS蛋白表面光滑， ...

2026 年欧洲肺癌大会（ELCC）将于 3 月 25 日至 28 日在丹麦哥本哈根盛大召开，作为全球胸部肿瘤领域最具影响力的学术盛会之一，本届大会汇聚了来自世界各地的顶尖专家、临床研究者共同探讨肺癌诊疗的重大突破与未来愿景。 KRAS 曾被视为「不可成药」靶点，但近年来，随着 KRAS 抑制剂的获批和临床应用，KRAS 突变晚期非小细胞肺癌（NSCLC）患者的治疗策略迎来了重大突破。本届 ELC ...

Setidegrasib results published in New England Journal of Medicine FORT MYERS, Fla., April 2, 2026 /PRNewswire/ -- Results of a Phase 1 clinical study conducted with participation from Florida Cancer ...

Tumors driven by cancer-driving KRAS mutations are often susceptible to ferroptosis, a type of cell death that can be ...

A common mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma (PDAC) compared with other variants, in part because the mutation appears to lead to ...

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In colon cancer, the second most common cause of cancer death, such mutations ...

This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.

Researchers at MUSC Hollings Cancer Center have discovered why a powerful cancer-causing gene mutation rarely appears in pancreatic tumors. The study, published in Cancer Research Communications, ...

SAN FRANCISCO and SUZHOU, China, Aug. 21, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...